Investigating Fractional Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease (COPD) and Asthma-COPD Overlap (ACO): A Scoping Review

References

• Kiljander T, Helin T, Venho K, Jaakkola A, Lehtimaki L. Prevalence of asthma-copd overlap syndrome among primary care asthmatics with a smoking history: a cross-sectional study. NPJ Prim Care Respir Med. 2015;25:15047.
   PubMed Web of Science ®Google Scholar
• Burgel PR, Paillasseur JL, Roche N. Identification of clinical phenotypes using cluster analyses in copd patients with multiple comorbidities. Biomed Res Int. 2014;2014:420134.
   PubMed Web of Science ®Google Scholar
• Feng JX, Lin Y, Lin J, He SS, Chen MF, Wu XM, Xu YZ. Relationship between fractional exhaled nitric oxide level and efficacy of inhaled corticosteroid in asthma-COPD overlap syndrome patients with different disease severity. J Korean Med Sci. 2017;32(3):439–447.
   PubMed Web of Science ®Google Scholar
• Chen FJ, Huang XY, Liu YL, Lin GP, Xie CM. Importance of fractional exhaled nitric oxide in the differentiation of asthma-COPD overlap syndrome, asthma, and COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2385–2390.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, et al. Evaluation of copd longitudinally to identify predictive surrogate end-points (eclipse). Eur Respir J. 2008;31(4):869–873.
   PubMed Web of Science ®Google Scholar
• Cataldo D, Corhay JL, Derom E, Louis R, Marchand E, Michils A, Ninane V, Peche R, Pilette C, Vincken W, et al. A belgian survey on the diagnosis of asthma-copd overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2017;12:601–613.
   PubMed Web of Science ®Google Scholar
• Aggarwal AN, Gupta D, Agarwal R, Jindal SK. Comparison of the lower confidence limit to the fixed-percentage method for assessing airway obstruction in routine clinical practice. Respir Care. 2011;56(11):1778–1784.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wittman R, Kesten S, Chapman KR. GINA-GOLD Diagnosis of diseases of chronic airflow limitation: Asthma, COPD and asthma-COPD overlap syndrome (ACOS). 2014. Chest. 1994;105.
   PubMedGoogle Scholar
• Soler-Cataluna JJ, Cosio B, Izquierdo JL, Lopez-Campos JL, Marin JM, Aguero R, Baloira A, Carrizo S, Esteban C, Galdiz JB, et al. Consensus document on the overlap phenotype copd-asthma in copd. Arch Bronconeumol. 2012;48(9):331–337.
   PubMed Web of Science ®Google Scholar
• Games E, Guerreiro M, Santana FR, Pinheiro NM, de Oliveira EA, Lopes FD, Olivo CR, Tiberio IF, Martins MA, Lago JH, et al. Structurally related monoterpenes p-cymene, carvacrol and thymol isolated from essential oil from leaves of lippia sidoides cham. (verbenaceae) protect mice against elastase-induced emphysema. Molecules. 2016;21(10):20.
   Web of Science ®Google Scholar
• Barnes PJ. Asthma-copd overlap. Chest. 2016;149(1):7–8.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A. The asthma-copd overlap syndrome: Towards a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3(9):719–728.
   PubMed Web of Science ®Google Scholar
• Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, Crapo JD, Hersh CP. The clinical features of the overlap between copd and asthma. Respir Res. 2011;12:127.
   PubMed Web of Science ®Google Scholar
• Menezes AM, Montes de Oca M, Perez-Padilla R, Nadeau G, Wehrmeister FC, Lopez-Varela MV, Muino A, Jardim JR, Valdivia G, Talamo C. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: Copd-asthma. Chest. 2014;145(2):297–304.
   PubMed Web of Science ®Google Scholar
• Kauppi P, Kupiainen H, Lindqvist A, Tammilehto L, Kilpelainen M, Kinnula VL, Haahtela T, Laitinen T. Overlap syndrome of asthma and copd predicts low quality of life. J Asthma. 2011;48(3):279–285.
   PubMed Web of Science ®Google Scholar
• Andersen H, Lampela P, Nevanlinna A, Saynajakangas O, Keistinen T. High hospital burden in overlap syndrome of asthma and copd. Clin Respir J. 2013;7(4):342–346.
   PubMed Web of Science ®Google Scholar
• Rhee CK, Yoon HK, Yoo KH, Kim YS, Lee SW, Park YB, Lee JH, Kim Y, Kim K, Kim J, et al. Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma. COPD. 2014;11(2):163–170.
   PubMedGoogle Scholar
• Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of copd: Identification, definition and implications for guidelines. Arch Bronconeumol. 2012;48(3):86–98.
   PubMed Web of Science ®Google Scholar
• Sin DD, Miravitlles M, Mannino DM, Soriano JB, Price D, Celli BR, Leung JM, Nakano Y, Park HY, Wark PA, et al. What is asthma-copd overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016;48(3):664–673.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Simpson JL. The overlap syndrome of asthma and copd: What are its features and how important is it? Thorax. 2009;64(8):728–735.
   PubMed Web of Science ®Google Scholar
• Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR. An official ats clinical practice guideline: interpretation of exhaled nitric oxide levels (feno) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Alving K, Diamant Z, Magnussen H, Pavord I, Piacentini G, Price D, Roche N, Sastre J, Thomas M, et al. Current evidence and future research needs for feno measurement in respiratory diseases. Respir Med. 2014;108(6):830–841.
   PubMed Web of Science ®Google Scholar
• Hart CM. Nitric oxide in adult lung disease. Chest. 1999;115(5):1407–1417.
   PubMed Web of Science ®Google Scholar
• Korhonen R, Lahti A, Kankaanranta H, Moilanen E. Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy. 2005;4(4):471–479.
   PubMedGoogle Scholar
• Alcazar-Navarrete B, Romero-Palacios PJ, Ruiz-Sancho A, Ruiz-Rodriguez O. Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of copd phenotypes. Nitric Oxide. 2016;54:67–72.
   PubMed Web of Science ®Google Scholar
• Essat M, Harnan S, Gomersall T, Tappenden P, Wong R, Pavord I, Lawson R, Everard ML. Fractional exhaled nitric oxide for the management of asthma in adults: a systematic review. Eur Respir J. 2016;47(3):751–768.
   PubMed Web of Science ®Google Scholar
• Tamada T, Sugiura H, Takahashi T, Matsunaga K, Kimura K, Katsumata U, Takekoshi D, Kikuchi T, Ohta K, Ichinose M. Biomarker-based detection of asthma-copd overlap syndrome in copd populations. Int J Chron Obstruct Pulmon Dis. 2015;10:2169–2176.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Herje N, Crater G, Rickard K. Characterization of airway inflammation in patients with copd using fractional exhaled nitric oxide levels: a pilot study. Int J Chron Obstruct Pulmon Dis. 2014;9:745–751.
   PubMed Web of Science ®Google Scholar
• Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141–146.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015 statement. Syst Rev. 2015;4:1.
   Google Scholar
• Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69.
   PubMed Web of Science ®Google Scholar
• Arksey H OML. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32.
   Google Scholar
• Mostafavi-Pour-Manshadi S-M-Y, Naderi N, Barrecheguren M, Dehghan A, Bourbeau J. Investigating fractional exhaled nitric oxide (feno) in chronic obstructive pulmonary disease (copd) and asthma–copd overlap (aco): A scoping review protocol. BMJ Open. 2017;7(12).
   PubMed Web of Science ®Google Scholar
• Horvath I, Barnes PJ, Loukides S, Sterk PJ, Hogman M, Olin AC, Amann A, Antus B, Baraldi E, Bikov A, et al. A European respiratory society technical standard: exhaled biomarkers in lung disease. Eur Respir J. 2017;49(4):pii: 1600965
   Web of Science ®Google Scholar
• Ats/ers recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med. 2005;171(8):912–930.
   PubMed Web of Science ®Google Scholar
• Stone PW. Popping the (pico) question in research and evidence-based practice. Appl Nurs Res. 2002;15(3):197–198.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Lillie E, Zarin W, O'Brien K, Colquhoun H, Kastner M, Levac D, Ng C, Sharpe JP, Wilson K, et al. A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol. 2016;16:15.
   PubMed Web of Science ®Google Scholar
• Pham MT, Rajic A, Greig JD, Sargeant JM, Papadopoulos A, McEwen SA. A scoping review of scoping reviews: advancing the approach and enhancing the consistency. Res Synth Methods. 2014;5(4):371–385.
   PubMed Web of Science ®Google Scholar
• Antus B, Barta I, Horvath I, Csiszer E. Relationship between exhaled nitric oxide and treatment response in copd patients with exacerbations. Respirology. 2010;15(3):472–477.
   PubMed Web of Science ®Google Scholar
• Bazeghi N, Gerds TA, Budtz-Jorgensen E, Hove J, Vestbo J. Exhaled nitric oxide measure using multiple flows in clinically relevant subgroups of copd. Respir Med. 2011;105(9):1338–1344.
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Seemungal TA, Donaldson GC, Wedzicha JA. Effects of exacerbations and seasonality on exhaled nitric oxide in copd. Eur Respir J. 2005;26(6):1009–1015.
   PubMed Web of Science ®Google Scholar
• de Laurentiis G, Maniscalco M, Cianciulli F, Stanziola A, Marsico S, Lundberg JO, Weitzberg E, Sofia M. Exhaled nitric oxide monitoring in copd using a portable analyzer. Pulm Pharmacol Ther. 2008;21(4):689–693.
   PubMed Web of Science ®Google Scholar
• Lehouck A, Carremans C, De Bent K, Decramer M, Janssens W. Alveolar and bronchial exhaled nitric oxide in chronic obstructive pulmonary disease. Respir Med. 2010;104(7):1020–1026.
   PubMed Web of Science ®Google Scholar
• Roy K, Smith J, Kolsum U, Borrill Z, Vestbo J, Singh D. Copd phenotype description using principal components analysis. Respir Res. 2009;10:41.
   PubMed Web of Science ®Google Scholar
• Tilemann L, Gindner L, Meyer F, Szecsenyi J, Schneider A. Differences in local and systemic inflammatory markers in patients with obstructive airways disease. Prim Care Respir J. 2011;20(4):407–414.
   PubMedGoogle Scholar
• Santini G, Mores N, Shohreh R, Valente S, Dabrowska M, Trove A, Zini G, Cattani P, Fuso L, Mautone A, et al. Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable copd and healthy smokers. J Breath Res. 2016;10(1):017102.
   PubMed Web of Science ®Google Scholar
• Ziora D, Dworniczak S, Kozielski J. Induced sputum metalloproteinases and their inhibitors in relation to exhaled nitrogen oxide and sputum nitric oxides and other inflammatory cytokines in patients with chronic obstructive pulmonary disease. J Physiol Pharmacol. 2008;(59 Suppl. 6):809–817.
   PubMedGoogle Scholar
• Liu J, Sandrini A, Thurston MC, Yates DH, Thomas PS. Nitric oxide and exhaled breath nitrite/nitrates in chronic obstructive pulmonary disease patients. Respiration. 2007;74(6):617–623.
   PubMed Web of Science ®Google Scholar
• Dummer JF, Epton MJ, Cowan JO, Cook JM, Condliffe R, Landhuis CE, Smith AD, Taylor DR. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med. 2009;180(9):846–852.
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Rice KL, Janoff EN, Rector TS, Niewoehner DE. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. Ther Adv Respir Dis. 2008;2(2):55–64.
   PubMedGoogle Scholar
• Logotheti H, Pourzitaki C, Tsaousi G, Aidoni Z, Vekrakou A, Ekaterini A, Gourgoulianis K. The role of exhaled nitric oxide in patients with chronic obstructive pulmonary disease undergoing laparotomy surgery – the noxious study. Nitric Oxide. 2016;61:62–68.
   PubMed Web of Science ®Google Scholar
• Antus B, Barta I. Relationship between exhaled nitric oxide and the frequency of severe acute exacerbation of copd: 3-year follow-up. Acta Physiol Hung. 2013;100(4):469–477.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Hanagama M, Yamanda S, Ishida M, Yanai M. Inflammatory biomarkers in asthma-copd overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016;11:2117–2123.
   PubMed Web of Science ®Google Scholar
• Akamatsu K, Matsunaga K, Sugiura H, Koarai A, Hirano T, Minakata Y, Ichinose M. Improvement of airflow limitation by fluticasone propionate/salmeterol in chronic obstructive pulmonary disease: What is the specific marker? Front Pharmacol. 2011;2:36.
   PubMed Web of Science ®Google Scholar
• Ji Z, Pan X, Ji F, Ni DT, Shang Y, Bai C. Fractional exhaled nitric oxide detection in treatment of asthma-chronic obstructive pulmonary disease overlap syndrome [Chinese]. Acad J Second Military Med Univ. 2016;37(10):1250–1255.
   Google Scholar
• Huang SY, Chou PC, Wang TY, Lo YL, Joa WC, Chen LF, Sheng TF, Chung KF, Wang CH, Kuo HP. Exercise-induced changes in exhaled no differentiates asthma with or without fixed airway obstruction from copd with dynamic hyperinflation. Medicine (Baltimore). 2016;95(15):e3400.
   PubMed Web of Science ®Google Scholar
• Rouhos A, Kainu A, Piirila P, Sarna S, Lindqvist A, Karjalainen J, Sovijarvi AR. Repeatability of exhaled nitric oxide measurements in patients with copd. Clin Physiol Funct Imaging. 2011;31(1):26–31.
   PubMed Web of Science ®Google Scholar
• Xia Q, Pan P, Wang Z, Lu R, Hu C. Fractional exhaled nitric oxide in bronchial inflammatory lung diseases. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014;39(4):365–370.
   PubMedGoogle Scholar
• Rawy AM, Mansour AI. Fraction of exhaled nitric oxide measurement as a biomarker in asthma and copd compared with local and systemic inflammatory markers. Egypt J Chest Dis Tuberc. 2015;64(1):13–20.
   Web of Science ®Google Scholar
• Beg MF, Alzoghaibi MA, Abba AA, Habib SS. Exhaled nitric oxide in stable chronic obstructive pulmonary disease. Ann Thorac Med. 2009;4(2):65–70.
   PubMed Web of Science ®Google Scholar
• Foschino Barbaro MP, Carpagnano GE, Spanevello A, Cagnazzo MG, Barnes PJ. Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. Int J Immunopathol Pharmacol. 2007;20(4):753–763.
   PubMed Web of Science ®Google Scholar
• Arif AA, Mitchell C. Use of exhaled nitric oxide as a biomarker in diagnosis and management of chronic obstructive pulmonary disease. J Prim Care Community Health. 2016;7(2):102–106.
   PubMed Web of Science ®Google Scholar
• Durmaz D, Goksu E, Kilic T, Ozbudak O, Eray O. The role of nitric oxide in predicting revisit of patients with exacerbated chronic obstructive pulmonary disease. J Emerg Med. 2015;48(2):247–253.
   PubMed Web of Science ®Google Scholar
• Deng DD, Zhou AY, Shuang QC, Chen P. The value of fractionated exhaled nitric oxide in the diagnosis of asthma-chronic obstructive pulmonary disease overlap syndrome. Chung-Hua Chieh Ho Ho Hu Hsi Tsa Chih – Chinese J Tuberculosis Respiratory Diseases. 2017;40(2):98–101.
   Google Scholar
• Goto T, Camargo CJ, Hasegawa K. Fractional exhaled nitric oxide levels in asthma-copd overlap syndrome: analysis of the national health and nutrition examination survey, 2007–2012. Int J Chron Obstruct Pulmon Dis. 2016;11:2149–2155.
   PubMed Web of Science ®Google Scholar
• Qian Y, Matson JB. Gasotransmitter delivery via self-assembling peptides: Treating diseases with natural signaling gases. Adv Drug Deliv. Rev. 2017;110–111:137–156.
   PubMed Web of Science ®Google Scholar
• Cosio BG, Perez de Llano L, Lopez Vina A, Torrego A, Lopez-Campos JL, Soriano JB, Martinez Moragon E, Izquierdo JL, Bobolea I, Callejas J, et al. Th-2 signature in chronic airway diseases: towards the extinction of asthma-copd overlap syndrome? Eur Respir J. 2017;49(5):pii: 1602397
   Google Scholar
• Chou KT, Su KC, Huang SF, Hsiao YH, Tseng CM, Su VY, Hung SC, Perng DW. Exhaled nitric oxide predicts eosinophilic airway inflammation in copd. Lung. 2014;192(4):499–504.
   PubMed Web of Science ®Google Scholar
• Gao J, Zhang M, Zhou L, Yang X, Wu H, Zhang J, Wu F. Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of copd. Int J Chron Obstruct Pulmon Dis. 2017;12:1287–1293.
   PubMed Web of Science ®Google Scholar
• Soter S, Barta I, Antus B. Predicting sputum eosinophilia in exacerbations of copd using exhaled nitric oxide. Inflammation. 2013;36(5):1178–1185.
   PubMed Web of Science ®Google Scholar
• Zhao H, Li R, Lv Y, Dong H, Yao L, Wu Y, Xiao G, Cai S. Albuterol inhalation increases feno level in steroid-naive asthmatics but not copd patients with reversibility. Clin Respir J. 2017;11(3):328–336.
   PubMed Web of Science ®Google Scholar
• Amer M, Cowan J, Gray A, Brockway B, Dummer J. Effect of inhaled β2-Agonist on Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease. PLoS One. 2016;11(6):e0157019.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2011. N Engl J Med. 2005;353.
   Google Scholar
• Ishiura Y, Fujimura M, Shiba Y, Ohkura N, Hara J, Kasahara K. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-copd overlap syndrome. Pulm Pharmacol Ther. 2015;35:28–33.
   PubMed Web of Science ®Google Scholar